Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer

Human telomerase reverse transcriptase (hTERT) is a target antigen for cancer immunotherapy in patients with non-small cell lung cancer (NSCLC). We have tested a novel hTERT vaccine, UV1, designed to give high population coverage. UV1 is composed of three synthetic long peptides containing multiple...

Full description

Bibliographic Details
Main Authors: Paal F. Brunsvig, Tormod Kyrre Guren, Marta Nyakas, Claudius H. Steinfeldt-Reisse, Wenche Rasch, Jon Amund Kyte, Hedvig Vidarsdotter Juul, Steinar Aamdal, Gustav Gaudernack, Else Marit Inderberg
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Immunology
Subjects:
non-small cell lung cancer
human telomerase reverse transcriptase
peptide
vaccine monotherapy
dose response
clinical efficacy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2020.572172/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2020.572172/full

Similar Items